Risk of tuberculosis is increased in Behçet’s disease compared to other rheumatological disorders after anti-TNFα treatments: a case series and review of the literature

Ümmügülsüm GAZEL1,*, Derya KOCAKAYA2, İrem HİCRET TOPÇU3, Hakan ÖMER KARATAŞ4, Murat KARABACAK2, Mehmet Pamir ATAGÜN'DÜZ4, Güzide Nevsun İNANÇ1, Fatma ALİBAZ ÖNER4, Rafi Haner DİRESKENELİ1

1Department of Rheumatology, Faculty of Medicine, Marmara University, İstanbul, Turkey
2Department of Pulmonary and Critical Care Medicine, Faculty of Medicine, Marmara University, İstanbul, Turkey
3School of Medicine, Marmara University, İstanbul, Turkey

* Correspondence: gulsumoguz@hotmail.com

1. Introduction

Tumor necrosis factor-alpha (TNF-α) antagonists are extensively utilized in the treatment of inflammatory rheumatic diseases such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). In recent years, experience with these agents has also increased in other immune rheumatological diseases. In Behçet’s disease (BD), a multisystemic inflammatory disorder, TNF-α antagonists are also shown to be effective in patients with major organ involvement, refractory to conventional immunosuppressives (IS) [1].

The risk of infections is shown to be increased with the use of TNF-α antagonists as a significant side effect [2].
diseases and to reveal the risk of TB according to the rheumatologic diagnosis, particularly BD. Factors associated with this risk are also assessed.

2. Methods

2.1. Patients and data collection

The data of 1277 patients who received TNF-a antagonists between 2005 and 2018 at Marmara University, School of Medicine, Rheumatology Outpatient Clinics, were assessed retrospectively. Patients had to have an inflammatory rheumatic disease treated with one of the TNF-a antagonists (Adalimumab, Infliximab, Etanercept, Golimumab, and Certolizumab Pegol) to be included in the study. Follow-up data were collected from standard patient report forms and medical chart reviews: demographic features, TNF-a antagonist type and treatment time, tuberculosis skin test (TST) (positive/negative) or QuantiFERON results, isoniazid prophylaxis status, concomitant CS treatment (yes/no). For TB patients, time until TB development and organ involvement type were also recorded.

2.2. Tuberculosis (TB) screening

Patients were screened for TB before and during the TNF-a antagonist treatments according to the Consensus Report on using TNF-a antagonists endorsed by the Rheumatology Society of Turkey [6]. Before starting TNF-a antagonists, patients were evaluated for TB by a questionnaire for the presence of prior TB infection or treatment with antituberculosis drugs and a history of contact with a tuberculosis-infected case. Additionally, patients were evaluated for the occurrence of TB signs and symptoms with a physical examination. At the same time, patients underwent TST or QuantiFERON test depending on the availability and Chest radiograph. If the TST result is \( \geq 5 \text{mm} \) or QuantiFERON test was positive, isoniazid (INH) prophylaxis 300 mg/day for nine months was started. In case of a suspicious finding for latent TB in the chest radiograph or in physical examination and anamnesis, INH prophylaxis was decided with a chest disease or infectious disease specialist, even if screening tests were negative. Patients were followed up every 3–6 months for the development of pulmonary or extra-pulmonary TB with symptom inquiry and physical examination. Chest radiographs were also repeated once a year. In the case of suspected TB infection during follow-up, an appropriate evaluation was made.

2.3. Statistics

Means of continuous variables and standard deviation when the data were distributed normally were calculated. Medians and first to third quartile intervals were calculated when data that did not have a normal distribution. Group differences for dependent categorical variables were analyzed with the Chi-square or Fishers’ exact test. Continuous variables were compared with student t-test or Mann–Whitney U when data were skewed. A two-tailed p-value < 0.05 was considered significant.

3. Results

3.1. Patient demographics

A total of 1277 (male/female = 597/680; median age = 49 years) patients were treated with TNF-a antagonist for a median of 33 months (Q1:12, Q3:62). During this period, 1560 different TNF-a antagonist prescriptions were started, Etanercept (n = 509, 33%) and Adalimumab (n = 509, 33 %) were the most frequently selected. The most common diagnosis were AS (n = 644; 51%) and RA (n = 477; 38%), respectively. Either TST or QuantiFERON tests were positive in 823 (65%) patients, and the rate of patients that used INH prophylaxis (872, 69%) was slightly more than test positivity. CS treatment data were collected in 795 patients as received/not received. Within this group, 38% of the patients received CS at any time during the follow-up period. The characteristics of all patients in the study are summarized in Table 1.

3.2. Patient characteristics with and without tuberculosis (TB)

Among 1277 patients, 13 (1%) of them developed TB during the follow-up period. While the median age of TB-positive and negative patients was similar (50 and 49 years, respectively), male presence was higher in TB-positive patients (76% vs. 24%). TST and/or QuantiFERON positivity and INH usage rates were comparable between the two groups. Although, the median time of (month) TNF-a antagonist treatment was higher in TB-positive patients than negative ones, the difference was not statistically significant (48 and 33 months, respectively, p = 0.47). Similarly, TB-positive patients were treated with CS more than TB-negatives (80% vs. 60%). The comparison of patients with and without TB is summarized in Table 1. All percentages are given based on the total number of patients with and without TB within the columns in Table 1.

Within 13 TB-positive patients, 6 of them had pulmonary, 6 had extra-pulmonary TB and 1 had both. Time from the initiation of TNF-a antagonist treatment to the diagnosis of TB had a median of 40 months (Q1-Q3: 22-56). At the time of TB diagnosis, all 13 patients were on anti-TNFa treatments (4 Etanercept, 5 Adalimumab, 2 Infliximab, and 2 Certolizumab Pegol). Due to disease activity, Certolizumab Pegol and Etanercept were started again after TB treatment for two patients with AS diagnosis.

According to the underlying disease, TB was more frequent in the AS group (n = 5, 0.7%) compared to the other diseases, but patients with BD (n = 3, 8.1%) had the highest rate for TB (Table 2). There was a statistically significant increase of TB development in BD patients than non-BD patients after TNF-a antagonists (7.5% vs. 0.8%, respectively, p = 0.007). When we combined our
patients with the other series from Turkey, among 12928 patients who received TNF-α antagonists, TB was positive in 12 (3.9%) of 305 BD patients compared to 112 (0.9%) of 12623 non-BD patients (p < 0.00001). A summary of all studies published from Turkey, which reported the TB incidence after TNF-α antagonists and comparison with the present study is given in Table 3.

Table 1. Characteristics of the patients treated with anti-TNF-α antagonists.

|                                | All patients (n = 1277) | Patients without TB (n = 1264) | Patients with TB (n = 13) | p*   |
|--------------------------------|-------------------------|--------------------------------|--------------------------|------|
| Age median (Q1-Q3), years      | 49 (39–58)              | 49 (39–58)                      | 50 (41–61)               | 0.514|
| Male                           | 597 (47)                | 587 (46.4)                      | 10 (77)                  | 0.046|
| TST and/or QuantiFERON Positivity | 823 (65)                | 815 (65)                        | 8 (61)                   | 0.530|
| INH prophylaxis                | 875/1268 (69)           | 867/1255 (69)                   | 8/13 (61)                | 0.556|
| Corticosteroid treatment (at any time) | 480/797 (60)         | 472/785 (60)                    | 8/10 (80)                | 0.330|
| Anti-TNFα treatment time median (Q1-Q3) (month) | 33 (12–62)             | 33 (12–62)                      | 48 (22–80)               | 0.470|

### Anti-TNFα treatment
- **Etanercept**: 509 (40) vs. 501 (40) vs. 8 (61) (p = 0.153)
- **Adalimumab**: 509 (40) vs. 504 (40) vs. 5 (38) (p = 1.000)
- **Infliximab**: 380 (30) vs. 375 (30) vs. 5 (38) (p = 0.544)
- **Certolizumab**: 84 (7) vs. 81 (6) vs. 3 (23) (p = 0.049)
- **Golimumab**: 78 (6) vs. 78 (6) vs. 0 (p = 1.000)

### Inflammatory disease
- **Rheumatoid arthritis**: 479 (38) vs. 475 (38) vs. 4 (30) (p = 0.777)
- **Ankylosing spondylitis**: 648 (51) vs. 643 (51) vs. 5 (38) (p = 0.415)
- **Psoriatic arthritis**: 96 (8) vs. 95 (8) vs. 1 (8) (p = 1.000)
- **Behçet’s disease**: 40 (3) vs. 37 (3) vs. 3 (23) (p = 0.007)
- **Takayasu’s arteritis**: 14 (1) vs. 14 (1) vs. 0 (p = 1.000)

Except where indicated otherwise, values are the number/total number (percent) of patients.

TNF: tumor necrosis factor; TB: tuberculosis; TST: tuberculosis skin test; INH: isoniazid.

*Comparison of patients with and without TB.

Table 2. The frequency of TB development according to the underlying disease.

| Disease                | Patients with TB (n) | Patients without TB (n) | %  |
|------------------------|----------------------|-------------------------|----|
| Rheumatoid arthritis   | 4                    | 475                     | 0.8|
| Ankylosing spondylitis | 5                    | 643                     | 0.7|
| Psoriatic arthritis    | 1                    | 95                      | 0.1|
| Behçet’s disease       | 3                    | 37                      | 8.1|
| Takayasu’s arteritis   | 0                    | 14                      | -  |

3.3. Comparison of BD patients with and without tuberculosis
Among 40 patients with BD, TB-positive patients (n = 3) were all male and had a slightly younger mean age than TB-negatives (34.6 vs. 39 years, respectively, p = 0.456). All TB-positive patients with BD used INH prophylaxis and had a positive TST/QuantiFERON. Median time (month)
of TNF-a antagonist and CS treatment rates were also slightly higher in TB-positive than TB negative patients with BD [(20 months vs 16 months, respectively, p = 0.939) and (3/3 100% vs 29/33 88%, respectively, p = 0.522)].

4. Discussion
This study confirmed the increased risk of TB after anti-TNFa treatments and suggested that this increased risk might be greater in BD compared to other rheumatic disorders.

TNF-a has an important role, particularly in the defense against mycobacteria and is essential for the maintenance of granuloma formation [7]. Other key functions of TNF-a include regulation of apoptosis, release of cytokines from activating macrophages, and effects on the formation of nitric oxide and the leucocyte movement [8]. Increased TB frequency after anti-TNFa treatments has been reported from large registries [9–12]. This increased risk has been reported more prominently for monoclonal antibodies Adalimumab and Infliximab compared to soluble receptors such as Etanercept. Although screening and prophylaxis improved much in recent years, TNF-a inhibition may affect some countries more seriously, such as Turkey, with a not too-low (22/100 000) incidence of TB. In a multicenter cohort study from Turkey, Kisacik et al. reported 73 TB-positive cases within 7768 patients treated with TNF-a antagonists [3]. In other publications from Turkey, Çağatay et al. reported 22 TB-positive cases within 1887 patients and Börekçi et al. 16 TB-positive cases within 1964 patients after TNF-a antagonists [13,14]. Our TB prevalence was similar to these other studies from Turkey (0.7-1.1%).

As both BD and TB infection are common diseases in Turkey, TB data among TNF-a antagonist treated patients deserve separate analysis. Apart from Turkey, a few case reports have been published in the literature on BD and TB coexistence [15-18]. In the series from Turkey, Kisacik et al. showed that TB development rate was higher in BD compared to other rheumatic diseases (5/129, 4%). TB rate was also reported higher in BD than other diseases by Çağatay et al. (1/53, 1.8%). Börekçi et al. also found BD to be associated with the development of TB infection in multivariate analysis (3/83, 3.6%, p = 0.003). We documented even a higher rate of TB among BD patients than other Turkish cohorts (3/40, 7.5 %). As a whole, the more frequent use of TNF-a antagonists in recent years in patients with major organ involvement, also suggested by the recent EULAR recommendations, requires more research on the infectious side-effects of anti-TNFa treatments in BD (1).

| | Börekçi et al., 2015 | Kisacik et al., 2016 | Çağatay et al., 2017 | Current study |
|---|---|---|---|---|
| Total number of patients treated with TNF-α antagonists (n) | 1964 | 7768 | 1887 | 1277 |
| Age years (mean ± SD) | 39.7 ± 13.9 | 43.4 ± 13.6 | 42.41 ± 12.71 | 48.7 ± 13.2 |
| Male/Female (n) | 1009/955 | 3673/4095 | 907/980 | 597/680 |
| TST/ QuantiFERON positivity, n (%) | 1162 (59) | 4243 (54.6) | 1127 (67.4) | 823 (65) |
| INH prophylaxis n (%) | 1250 (63.6) | 5704 (73.4) | NR | 872 (69) |
| Time from initiation of TNF-a antagonist treatment to the diagnosis of TB | mean ± SD: 26.8 ± 17.1 months (range 1–60, median 26.5) | IFX: 13 months (range 1–96), ADA: 13 months (range 3–36), ETN: 7 months (range 4–60) | mean ± SD: 25.7 ± 19.4 | median: 40 months (Q1-Q3: 22–56) |
| TB positivity, n (%) | Behçet's disease | Other diseases | | |
| | 3/83 (3.6) | 13/1881 (0.7) | 5/129 (4) | 68/7639 (0.8) | 1/53 (1.8) | 21/1866 (1.1) | 3/40 (7.5) | 10/1237 (0.8) |

TNF: tumor necrosis factor; TB: tuberculosis; TST: tuberculosis skin test; INH: isoniazid; NR: not reported; IFX: infliximab; ADA: adalimumab; ETN: etanercept; SD: standard deviation.
Some underlying mechanisms may be suggested for this higher TB prevalence after anti-TNFα exposure in BD. Patients with major-organ BD are generally males at a younger age and usually actively participate in the workforce, which may cause more contact with mycobacteria compared to other patient groups. The fact that BD patients have lower socio-economic status may be another reason [4,5]. Higher CS doses (0.5-1 mg/kg/day), especially used in the initial use of TNFα antagonists, to suppress major organ damage such as vision loss or arterial complications may also contribute to the development of TB. Immune mechanisms leading to BD activation, such as augmented innate immunity and male sex-related effects, might also predispose BD patients to mycobacterial infections. Finally, some HLA genes are associated with tuberculous TB. Immune mechanisms leading to BD activation, such as augmented innate immunity and male sex-related effects, might also predispose BD patients to mycobacterial infections. In conclusion, our results suggest a higher frequency of TB infections in BD patients with TNFα antagonists. As biologic agents are increasingly used for major organ involvement in current practice for BD, screening mechanisms should be carefully implemented and followed.

Informed consent
Study protocol was approved by Marmara University Local Ethics Committee (approval number: 09.2020.978) and the study was performed according to the Declaration of Helsinki. Patient informed consent was not required for being a retrospective data collection.

References

1. Hartemi G, Christensen R, Bang D, Bodaghi B, Celik AF et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Annals of the Rheumatic Disease 2018; 77 (6): 808-818. doi: 10.1136/annrheumdis-2018-213225

2. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003; 42 (5): 617-621.

3. Kisacik B, Pamuk ON, Onat AM, Ezer SB, Hatemi G et al. Characteristics Predicting tuberculosis risk under tumor necrosis factor-alpha inhibitors: report from a large multicenter cohort with high background prevalence. The Journal of Rheumatology 2016; 43 (3): 524-539. doi: 10.3899/jrheum.150177

4. Direkscnelli H, Mumcu G. A possible decline in the incidence and severity of Behçet’s disease: implications for an infectious etiology and oral health. Clinical and Experimental Rheumatology 2010; 28 (4 Suppl 60): 86-90. PMID: 20868578

5. Pehlivan M, Kürümçü M, Tüzün E, Shugaiv E, Mutlu M et al. The comparison of socio-economic conditions and personal hygiene habits of neuro-Behçet’s disease and multiple sclerosis patients. International Journal of Hygiene and Environmental Health 2011; 214 (4): 335-337. doi: 10.1016/j.ijheh.2011.04.001

6. Keser GDH, Akkoç N. Rheumatology Research and Education Foundation's Consensus Report on using TNF-alpha inhibitors 2005.

7. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheumatology 2001; 45 (1): 101-106. PMID: 11380854

8. Stenger S. Immunological control of tuberculosis: role of tumour necrosis factor and more. Annals of the Rheumatic Disease 2005; 64 Suppl 4: 24-28. doi: 10.1136/ard.2005.042531

9. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Annals of the Rheumatic Disease 2013; 72 (1): 37-42. doi: 10.1136/annrheumdis-2011-200690

10. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheumatology 2003; 48 (8): 2122-2127. doi: 10.1002/art.11137

11. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the Rheumatic Disease 2010; 69 (3): 522-528. doi: 10.1136/ard.2009.11935

12. Tubach F, Salmon D, Ravaud P, Allonore Y, Goupille P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheumatology 2009; 60 (7): 1884-1894. doi: 10.1002/art.24632

13. Cagatay T, Bingol Z, Kiyen E, Yegen Z, Okumus G et al. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk. The Clinical Respiratory Journal 2018; 12 (4): 1668-1675. doi: 10.1111/crj.12726

14. Boekci S, Atahan E, Demir Yilmaz D, Mazican N, Duman B et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-alpha treatment. Respiration 2015; 90 (3): 191-198. doi: 10.1159/000434684
15. Iliopoulos A, Kedikoglou S, Laxanis S, Kourouklis S, Katsaros E. A case of tuberculous meningoencephalitis in a patient with Behçet’s disease. Clinical Rheumatology 2006; 25 (1): 121-122. doi: 10.1007/s10067-005-1135-4

16. Yan Shen H-fM, Yan-li Yang, Jian-long Guan. Ulcerative intestinal tuberculosis case as a complication of treatment by infliximab for intestinal Behçet’s disease: a case report. Medicine (Baltimore) 2019; 98 (43): e17652. doi: 10.1097/MD.0000000000017652

17. Freitas SM, Marques JS, Grilo A, Gomes R, Goncalves FM. Behçet’s disease and tuberculosis: a complex relationship. European Journal of Case Reports in Internal Medicine 2020; 7 (2): 001354. doi: 10.12890/2020_001354

18. Skvara H, Duschek N, Karlhofer F. De novo tuberculosis during infliximab therapy in a patient with Behçet disease. Journal of the German Society of Dermatology 2009; 7 (7): 616-619. doi: 10.1111/j.1610-0387.2009.07040.x

19. Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G et al. Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. The Lancet Infectious Disease 2018; 18 (3): 64-75. doi: 10.1016/S1473-3099(17)30623-0

20. Sveinbjornsson G, Gudbjartsson DF, Halldorsson BV, Kristinsson KG, Gottfredsson M et al. HLA class II sequence variants influence tuberculosis risk in populations of European ancestry. Nature Genetics 2016; 48 (3): 318-322. doi: 10.1038/ng.3498

21. Hwang CH, Khan S, Ende N, Mangura BT, Reichman LB et al. The HLA-A, -B, and -DR phenotypes and tuberculosis. The American Review of Respiratory Disease 1985; 132 (2): 382-385. doi: 10.1164/arrd.1985.132.2.382

22. Hafez M, el-Salab S, el-Shennawy F, Bassiony MR. HLA-antigens and tuberculosis in the Egyptian population. Tubercle 1985; 66 (1): 35-40. doi: 10.1016/0041-3879(85)90051-0

23. Hughes T, Coit P, Adler A, Yilmaz V, Aksu K et al. Identification of multiple independent susceptibility loci in the HLA region in Behçet’s disease. Nature Genetics 2013; 45 (3): 319-324. doi: 10.1038/ng.2551

24. McGonagle D, Aydin SZ, Gül A, Mahr A, Direskeneli H. 'MHC-I-opathy'-unified concept for spondyloarthritis and Behçet disease. Nature Reviews Rheumatology 2015; 11 (12): 731-740. doi: 10.1038/nrrheum.2015.147